Published in J Biol Chem on June 11, 2002
RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci U S A (2004) 2.53
Smooth muscle cell calcium activation mechanisms. J Physiol (2008) 2.12
Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am (2005) 1.81
A pathophysiology-based approach to the management of early priapism. Asian J Androl (2012) 1.35
Hydrogen sulfide as a mediator of human corpus cavernosum smooth-muscle relaxation. Proc Natl Acad Sci U S A (2009) 1.29
Endothelial nitric oxide synthase keeps erection regulatory function balance in the penis. Eur Urol (2006) 1.13
Attenuated RhoA/Rho-kinase signaling in penis of transgenic sickle cell mice. Urology (2010) 0.95
Modulation of spontaneous Ca2+-activated Cl- currents in the rabbit corpus cavernosum by the nitric oxide-cGMP pathway. J Physiol (2004) 0.94
Expression of Rho-kinase and its functional role in the contractile activity of the mouse vas deferens. Br J Pharmacol (2003) 0.94
Emerging role for TNF-α in erectile dysfunction. J Sex Med (2010) 0.93
Understanding and targeting the Rho kinase pathway in erectile dysfunction. Nat Rev Urol (2014) 0.93
Involvement of beta 3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function. Proc Natl Acad Sci U S A (2003) 0.90
Gas what: NO is not the only answer to sexual function. Br J Pharmacol (2014) 0.89
Priapism in sickle cell anemia: emerging mechanistic understanding and better preventative strategies. Anemia (2010) 0.87
Caspase-3 dependent nitrergic neuronal apoptosis following cavernous nerve injury is mediated via RhoA and ROCK activation in major pelvic ganglion. Sci Rep (2016) 0.85
Up-regulation of the RhoA/Rho-kinase signaling pathway in corpus cavernosum from endothelial nitric-oxide synthase (NOS), but not neuronal NOS, null mice. J Pharmacol Exp Ther (2010) 0.84
Erectile properties of the Rho-kinase inhibitor SAR407899 in diabetic animals and human isolated corpora cavernosa. J Transl Med (2012) 0.82
The Rho-kinase inhibitor Y-27632 and the soluble guanylyl cyclase activator BAY41-2272 relax rabbit vaginal wall and clitoral corpus cavernosum. Br J Pharmacol (2003) 0.78
Aging impairs Ca2+ sensitization pathways in gallbladder smooth muscle. Age (Dordr) (2011) 0.77
Molecular pathophysiology of priapism: emerging targets. Curr Drug Targets (2015) 0.76
Nitrergic Mechanisms for Management of Recurrent Priapism. Sex Med Rev (2015) 0.75
cAMP-dependent regulation of RhoA/Rho-kinase attenuates detrusor overactivity in a novel mouse experimental model. BJU Int (2017) 0.75
Hydrochlorothiazide Potentiates Contractile Activity of Mouse Cavernosal Smooth Muscle. Sex Med (2016) 0.75
Association of nNOS and Rho-kinase with age-associated erectile dysfunction in Sprague-Dawley rats. Exp Ther Med (2017) 0.75
Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev (2003) 9.32
Prevalence of and risk factors for urine leakage in a racially and ethnically diverse population of adults: the Boston Area Community Health (BACH) Survey. Am J Epidemiol (2008) 3.02
Ca2+-dependent rapid Ca2+ sensitization of contraction in arterial smooth muscle. Circ Res (2006) 2.79
Urinary retention and post-void residual urine in men: separating truth from tradition. J Urol (2008) 2.57
Urologic complications of diabetes. Diabetes Care (2005) 2.03
Current and future need for academic urologists in the United States. J Urol (2011) 1.86
Phosphorylation of the myosin phosphatase targeting subunit and CPI-17 during Ca2+ sensitization in rabbit smooth muscle. J Physiol (2003) 1.86
Angiotensin II, focal adhesion kinase, and PRX1 enhance smooth muscle expression of lipoma preferred partner and its newly identified binding partner palladin to promote cell migration. Circ Res (2007) 1.76
Patient-centered goals for pelvic floor dysfunction surgery: what is success, and is it achieved? Am J Obstet Gynecol (2002) 1.58
Nitric oxide-induced biphasic mechanism of vascular relaxation via dephosphorylation of CPI-17 and MYPT1. J Physiol (2009) 1.50
The crystal structure of RhoA in complex with the DH/PH fragment of PDZRhoGEF, an activator of the Ca(2+) sensitization pathway in smooth muscle. Structure (2004) 1.45
Erection of the human penis and its morphological and vascular basis by Guiseppe Conti. J Sex Med (2008) 1.45
Increased phosphodiesterase type 5 levels in a mouse model of type 2 diabetes mellitus. J Sex Med (2012) 1.43
Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol (2002) 1.39
Pharmacologic management of painful bladder syndrome/interstitial cystitis: a systematic review. Arch Intern Med (2007) 1.38
The electronic medical record: how not to communicate. J Urol (2013) 1.38
Patient-centered goals for pelvic floor dysfunction surgery: long-term follow-up. Am J Obstet Gynecol (2004) 1.37
Surgical versus nonsurgical treatment of women with pelvic floor dysfunction: patient centered goals at 1 year. J Urol (2008) 1.34
Phosphorylation-dependent autoinhibition of myosin light chain phosphatase accounts for Ca2+ sensitization force of smooth muscle contraction. J Biol Chem (2009) 1.32
Is abuse causally related to urologic symptoms? Results from the Boston Area Community Health (BACH) Survey. Eur Urol (2007) 1.29
Assessment of contractility of purified smooth muscle cells derived from embryonic stem cells. Stem Cells (2006) 1.29
Phosphorylation of the myosin phosphatase inhibitors, CPI-17 and PHI-1, by integrin-linked kinase. Biochem J (2002) 1.29
Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry. J Urol (2011) 1.25
Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants. FASEB J (2003) 1.20
Smooth muscle myosin: regulation and properties. Philos Trans R Soc Lond B Biol Sci (2004) 1.20
Cooperativity between the Ras-ERK and Rho-Rho kinase pathways in urokinase-type plasminogen activator-stimulated cell migration. J Biol Chem (2002) 1.17
Rho-kinase: regulation, (dys)function, and inhibition. Biol Chem (2013) 1.17
Agonist- and depolarization-induced signals for myosin light chain phosphorylation and force generation of cultured vascular smooth muscle cells. J Cell Sci (2006) 1.13
Corticotropin releasing factor: a mediator of emotional influences on bladder function. J Urol (2004) 1.12
ROCK mediates phorbol ester-induced apoptosis in prostate cancer cells via p21Cip1 up-regulation and JNK. J Biol Chem (2009) 1.10
Myocardin is differentially required for the development of smooth muscle cells and cardiomyocytes. Am J Physiol Heart Circ Physiol (2011) 1.10
RhoA-Rho kinase pathway mediates thrombin- and U-46619-induced phosphorylation of a myosin phosphatase inhibitor, CPI-17, in vascular smooth muscle cells. Am J Physiol Cell Physiol (2005) 1.10
Thromboxane A2-induced bi-directional regulation of cerebral arterial tone. J Biol Chem (2008) 1.08
Signal transduction through the RhoA/Rho-kinase pathway in smooth muscle. J Muscle Res Cell Motil (2004) 1.07
Cep57, a multidomain protein with unique microtubule and centrosomal localization domains. Biochem J (2008) 1.06
Smooth and cardiac muscle-selective knock-out of Kruppel-like factor 4 causes postnatal death and growth retardation. J Biol Chem (2010) 1.06
p63RhoGEF couples Gα(q/11)-mediated signaling to Ca2+ sensitization of vascular smooth muscle contractility. Circ Res (2011) 1.05
On the mechanism of autoinhibition of the RhoA-specific nucleotide exchange factor PDZRhoGEF. BMC Struct Biol (2009) 1.04
The cAMP-responsive Rap1 guanine nucleotide exchange factor, Epac, induces smooth muscle relaxation by down-regulation of RhoA activity. J Biol Chem (2011) 1.04
Fiberoptic imaging of cavernous nerves in vivo. J Urol (2007) 1.04
Diagnosis and management of epididymitis. Urol Clin North Am (2008) 1.02
The role of corticotropin releasing factor and its antagonist, astressin, on micturition in the rat. Auton Neurosci (2005) 1.02
Telokin mediates Ca2+-desensitization through activation of myosin phosphatase in phasic and tonic smooth muscle. J Muscle Res Cell Motil (2005) 1.00
CPI-17-deficient smooth muscle of chicken. J Physiol (2004) 0.99
LPP, a LIM protein highly expressed in smooth muscle. Am J Physiol Cell Physiol (2003) 0.99
Relationship of lifestyle and clinical factors to lower urinary tract symptoms: results from Boston Area Community Health survey. Urology (2007) 0.99
Deletion of the protein kinase A/protein kinase G target SMTNL1 promotes an exercise-adapted phenotype in vascular smooth muscle. J Biol Chem (2008) 0.96
Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int (2006) 0.96
Reconstituted human myosin light chain phosphatase reveals distinct roles of two inhibitory phosphorylation sites of the regulatory subunit, MYPT1. Biochemistry (2014) 0.95
The association of depression, anxiety and nocturia: a systematic review. J Urol (2013) 0.95
Myosin regulatory light chain phosphorylation and strain modulate adenosine diphosphate release from smooth muscle Myosin. Biophys J (2004) 0.95
The actin-associated protein Palladin is required for development of normal contractile properties of smooth muscle cells derived from embryoid bodies. J Biol Chem (2008) 0.94
Cryo-atomic force microscopy of unphosphorylated and thiophosphorylated single smooth muscle myosin molecules. J Biol Chem (2003) 0.93
An improved approach to followup care for the urological patient: drop-in group medical appointments. J Urol (2006) 0.93
The actin associated protein palladin is important for the early smooth muscle cell differentiation. PLoS One (2010) 0.93
Tadalafil increases Akt and extracellular signal-regulated kinase 1/2 activation, and prevents apoptotic cell death in the penis following denervation. J Urol (2007) 0.92
The neurogenic bladder: an update with management strategies for primary care physicians. Med Clin North Am (2011) 0.92
Interleukin 6 mediates production of interleukin 10 in metastatic melanoma. Cancer Immunol Immunother (2011) 0.91
Phosphorylation of the myosin-binding subunit of myosin phosphatase by Raf-1 and inhibition of phosphatase activity. J Biol Chem (2001) 0.91
Structure of a constitutively activated RhoA mutant (Q63L) at 1.55 A resolution. Acta Crystallogr D Biol Crystallogr (2003) 0.91
Phosphorylation of protein phosphatase type-1 inhibitory proteins by integrin-linked kinase and cyclic nucleotide-dependent protein kinases. Biochem Biophys Res Commun (2003) 0.90
Modulation of Ca2+ sensitivity by cyclic nucleotides in smooth muscle from protein kinase G-deficient mice. J Biol Chem (2003) 0.89
Uncoupling of GPCR and RhoA-induced Ca2+-sensitization of chicken amnion smooth muscle lacking CPI-17. FEBS Lett (2004) 0.89
The association of adiposity and overactive bladder appears to differ by gender: results from the Boston Area Community Health survey. J Urol (2011) 0.89
Are statin medications associated with lower urinary tract symptoms in men and women? Results from the Boston Area Community Health (BACH) Survey. Ann Epidemiol (2011) 0.88
New roads leading to Ca2+ sensitization. Circ Res (2002) 0.88
Reciprocal regulation controlling the expression of CPI-17, a specific inhibitor protein for the myosin light chain phosphatase in vascular smooth muscle cells. Am J Physiol Cell Physiol (2012) 0.88
Patient-centered treatment goals for pelvic floor disorders: association with quality-of-life and patient satisfaction. Am J Obstet Gynecol (2009) 0.88
Alterations in voiding frequency and cystometry in the clomipramine induced model of endogenous depression and reversal with fluoxetine. J Urol (2003) 0.87
Mechanical properties of the extracellular matrix alter expression of smooth muscle protein LPP and its partner palladin; relationship to early atherosclerosis and vascular injury. J Muscle Res Cell Motil (2009) 0.87
Fluorescence linked enzyme chemoproteomic strategy for discovery of a potent and selective DAPK1 and ZIPK inhibitor. ACS Chem Biol (2013) 0.87
Insights into the molecular activation mechanism of the RhoA-specific guanine nucleotide exchange factor, PDZRhoGEF. J Biol Chem (2011) 0.87
Expression of CPI-17 in smooth muscle during embryonic development and in neointimal lesion formation. Histochem Cell Biol (2009) 0.86
Are commonly used psychoactive medications associated with lower urinary tract symptoms? Eur J Clin Pharmacol (2011) 0.86
Cyclic GMP regulation of myosin phosphatase: a new piece for the puzzle? Circ Res (2007) 0.86
COPING with publication ethics. J Urol (2011) 0.86
Agonist-induced Ca2+ sensitization in smooth muscle: redundancy of Rho guanine nucleotide exchange factors (RhoGEFs) and response kinetics, a caged compound study. J Biol Chem (2013) 0.86
Pharmacologic treatment of erectile dysfunction. Rev Urol (2002) 0.85
Associations of commonly used medications with urinary incontinence in a community based sample. J Urol (2012) 0.84
Distinctive solution conformation of phosphatase inhibitor CPI-17 substituted with aspartate at the phosphorylation-site threonine residue. J Mol Biol (2003) 0.84
Intracellular chloride accumulation and subcellular elemental distribution during atrial fibrillation. Circulation (2003) 0.84
Bladder and urethral function in a mouse model of cavernous nerve injury. Neurourol Urodyn (2012) 0.83
p63RhoGEF: a new switch for G(q)-mediated activation of smooth muscle. Trends Cardiovasc Med (2012) 0.83
Domains of type 1 protein phosphatase inhibitor-2 required for nuclear and cytoplasmic localization in response to cell-cell contact. J Cell Sci (2002) 0.83
Confocal fluorescence microscopy in a murine model of microdissection testicular sperm extraction to improve sperm retrieval. J Urol (2012) 0.83